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Multiple sclerosis (MS) is a chronic inflammatory, neurodegenerative disease of the
CNS whose pathogenesis remains largely unknown, and available therapies are rarely
successful in reversing neurological deficits or stopping disease progression. Ongoing
studies on MS and the widely used murine model of experimental autoimmune
encephalomyelitis (EAE) are focused on the many components of this complex and
heterogeneous neurodegenerative disease in the hope of providing a mechanism-based
characterization of MS that will afford successful strategies to limit and repair the neuronal
damage. Recently, histamine has been postulated to have a key regulatory role in EAE
and MS pathogenesis. Histamine is a mediator of inflammation and immune responses,
exerting its many actions through four G protein-coupled receptors (H1,2,3,4R) that signal
through distinct intracellular pathways and have different therapeutic potentials as they
vary in expression, isoform distribution, signaling properties, and function. Immune cells
involved in MS/EAE, including dendritic cells (DCs) and T lymphocytes, express H1R, H2R
and H4R, and histamine may have varying and counteracting effects on a particular cell
type, depending on the receptor subtypes being activated. Here, we review evidence of
the complex and controversial role of histamine in the pathogenesis of MS and EAE and
evaluate the therapeutic potential of histaminergic ligands in the treatment of autoimmune
diseases.
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MS: A COMMON INFLAMMATORY-DEGENERATIVE
CNS DISEASE
Multiple sclerosis (MS) is the most common, non-traumatic
cause of neurological disability among young adults in Western
Europe and North America. The current hypothesis asserts that
MS is triggered by environmental factors in individuals with com-
plex genetic-risk profiles. As with other autoimmune diseases, MS
shows moderate polygenic inheritability and may be caused or
exacerbated by environmental exposure such as viral infections or
vitamin D deficiency (Correale et al., 2009). It is characterized by
clinical and genetic heterogeneity and with individuals withMHC
class II complex genes being most susceptible (Ballerini et al.,
2004; Gourraud et al., 2011). Out of the MHC locus a plethora of
genes have been described as minor contributors to genetic risk,
among which are those encoding for IL-2 receptors and IFN-γ
(Blankenhorn et al., 2011).
MS is characterized by inflammation of the central ner-
vous system (CNS) in which focal lymphocytic infiltrations lead
to damage of myelin and axons associated with neurological
Abbreviations: APCs, antigen presenting cells; BBB, blood brain barrier; DCs,
dendritic cells; EAE, experimental autoimmune encephalomyelitis; HDC, histidine
decarboxylase; MOG35–55, Myelin Oligodendrocyte Glycoprotein; MS, multiple
sclerosis; PLP139–151, myelin proteolipid protein.
dysfunction. Initially, the inflammatory response is transient and
remyelination occurs, but this is not durable and over time
widespread microglial activation ensues along with extensive and
chronic neurodegeneration.
The observation that histamine may be implicated inMS dates
back to the early 1980s when Tuomisto et al. (1983) showed
that patients with remitting or progressive disease have histamine
levels about 60% higher than controls. Another clinical study,
though, did not show elevated concentrations of histamine and
its metabolite methylhistamine inMS patients when compared, in
this case, with individuals affected by other neurological diseases
(Rozniecki et al., 1995). More recently, gene-microarray analy-
sis has shown that histamine H1 receptor (H1R) expression is
upregulated inMS lesions (Lock et al., 2002), and epidemiological
studies suggest a protective effect of brain penetrating H1R antag-
onists (Alonso et al., 2006). Furthermore, in a small pilot study,
a cohort of MS patients treated with an H1R antagonist showed
signs of neurological amelioration (Logothetis et al., 2005). The
H1R has long been associated with inflammatory responses and
for decades, the antiallergic and antiinflammatory activities of
H1R antagonists have been used in therapy. Possible explanations
of the therapeutic potential of H1R antagonists come from pre-
clinical results in experimental allergic encephalomyelitis (EAE)
in mice.
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EAE IS A GOOD MODEL FOR STUDYING MS
Pathological features of MS are studied in three main animal
models: toxic induction of disease, viral induction, and sev-
eral types of EAE. Cuprizone and lysolecithine, for example, are
used to investigate demyelination and remyelination in the CNS
(reviewed in Woodruff and Franklin, 1999; Kipp et al., 2009),
and to investigate how viral infections can induce CNS autoim-
munity; Theiler’s murine encephalomyelitis virus (TMEV) inoc-
ulated intracerebrally is a currently used experimental protocol
(Olson et al., 2001). EAE may be actively induced by immuniza-
tion of susceptible mouse strains with myelin proteins or myelin
protein immunodominant peptides in the presence of complete
Freund’s adjuvant (CFA), or may be passively induced by transfer
of myelin specific T cells. EAE, in most animal models, is mainly
driven by MHC class II restricted, autoimmune CD4+ T cells
and the clinical course depends on the immunization protocol, as
not all combinations of genetic background, antigen, and adju-
vant induce EAE. Classically, EAE immunized animals develop
an ascending flaccid paralysis from tail to head with variable dis-
ease score; manifestation of clinical symptoms may be relapsing
remitting, monophasic, or chronic. In active disease pathogenesis
of EAE, two main steps are usually described: priming of myelin-
reactive T cells and CNS invasion through the blood brain barrier
(BBB). Once cells invade the CNS, local, and infiltrated anti-
gen presenting cells (APCs) will present myelin peptides for full
activation. Many different types of cells contribute to the devel-
opment of the disease: APCs, mainly dendritic cells (DCs), B cells,
microglia, macrophages, and astrocytes, although astrocytes have
an unclear function in EAE development (Volterra andMeldolesi,
2005).
For many years the principal paradigm of EAE pathogene-
sis has been centered on IFN-γ producing T cells (Th1). These
cells differentiate upon exposure to IL-12 and IFN-γ, are char-
acterized by transcription factors T-bet, STAT1, STAT4 and are
found as infiltrates in CNS lesions. With time this paradigm has
been partially revised and a recently described T cell subpopula-
tion has been shown to have a central role in disease pathology:
Th17 cells that differentiate in the presence of IL-6 and TGF-β and
need RORγt as a transcription factor (Gutcher and Becher, 2007).
Th17 cells have been extensively studied in several autoimmune
diseases and there is wide agreement on the instability of the phe-
notype that may switch between Th1 and Th17. This plasticity
derives from epigenetic factors with Th17-derived Th1 cells pro-
moting autoimmune diseases (Annunziato et al., 2007; Mukasa
et al., 2010). Altogether, the studies on CD4+ T cells involved in
EAE do not ascribe a particular role to one specific T cell popu-
lation, and T helper cells may undergo alterations. Furthermore,
recent observations suggest that EAE can elicit both Th1 and Th2
immune responses in the same subjects, i.e., elements of the Th2
cell-mediated allergic response are associated with autoimmune
demyelination (Pedotti et al., 2003).
In conclusion, EAE has provided mechanistic insights into
the complex pathogenesis of MS and has proven to be a good
model for the preclinical testing of new diagnostic or treat-
ment modalities. In addition, it is considered a well-suited model
because of its histopathological and immunological similarities
to MS (Schreiner et al., 2009). Consequently, the large majority
of studies looking for a possible implication of histamine in
autoimmune diseases have been performed using themurine EAE
experimental model.
HISTAMINE IN AUTOIMMUNE DISEASES
Histamine has long been known to be a major promoter of
allergic inflammatory conditions and gastric acid secretion.
Synthesized by histidine decarboxylase (HDC) from histidine,
histamine was later described as a neurotransmitter in the CNS
that regulates several physiological processes and homeostatic
functions including cognition, arousal, circadian, and feeding
rhythms (Haas et al., 2008). These effects are mediated through
four distinct G protein-coupled receptors (H1R, H2R, H3R, and
H4R) with very low sequence homology. The H1R couples to
Gq proteins, leading to phospholipase C activation and calcium
mobilization (Bakker et al., 2002). The H2R activates Gαs and
increases camp formation, whereas the H3R mediates its function
through Gαi/o, inhibits cAMP synthesis (Bakker et al., 2002), acti-
vates MAP kinases and the AKT/GSK3β axis (Bongers et al., 2007;
Mariottini et al., 2009).
Inflammatory responses consequent to histamine release have
long been thought to be mediated by the H1R, and antihistamines
commonly used to treat allergies are H1R antagonists. The dis-
covery of a fourth histamine receptor (H4R) and its expression
on virtually all inflammatory and immune cells, though, has
prompted a reassessment of the role of histamine in inflam-
matory and immune disorders and widened the spectrum of
potential therapeutic interventions (Thurmond et al., 2008). The
H4R is coupled to Gαi/o proteins (Liu et al., 2001) and to the
β-arrestin pathway (Rosethorne and Charlton, 2011), and sig-
nals via intracellular increases of calcium. Its functions include
mediation of calcium mobilization, shape change, actin poly-
merization (Barnard et al., 2008) chemotaxis of mast cells,
and eosinophils (Buckland et al., 2003), and up-regulation of
adhesion molecules (Buckland et al., 2003).
All histamine receptors are expressed on the complement of
cells involved in autoimmune diseases, with the exception of the
H3R that is normally not expressed by hematopoietic cells, but
is mostly confined to the CNS (Passani et al., 2011b). Histamine
participates in the development and progression of EAE as it
controls accessibility to the site of inflammation by modulating
vasopermeability and adhesion molecule expression, chemotaxis,
and the cytokine profile of DCs and T lymphocytes, the main
players in autoimmune diseases.
ROLE OF HISTAMINE RECEPTORS IN EAE:
CONTROVERSIAL RESULTS
The regulatory functions of histamine relevant to the onset and
progression of neuroinflammatory diseases and in particular
EAE, are being studied in genetically modified mice lacking his-
taminergic receptors, and with relatively selective agonists and
antagonists. Hence, the contribution of each histamine receptor
in autoimmune diseases has been identified. Histamine plays a
complex role with varying and counteracting effects, depending
on the receptor subtypes being activated and the targeted tissue
(see Table 1). In vitro experiments have shown that activation
of H1R and H2R on DCs modulates cytokine and chemokine
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Table 1 | Histamine receptors and EAE.
Histamine EAE Investigated Pharmacological Disease Reference
receptor cell types target outcome
H1 SJL mice
PLP139–151
Increased H1R
expression on Th1
cells
H1R antagonism Less severe disease Pedotti et al., 2003
Humoral
immunoresponses
El Behi et al., 2007
MOG35–55
H1R-KO mice
CD4+T cells Reduced IFN-γ,
increased IL-4
Less severe disease
Ma et al., 2002
Noubade et al., 2007
MOG35–55
H1R-KO mice
Endothelial cells H1R overexpression Restored BBB integrity
Less severe disease
Lu et al., 2010
PLP139–151
SJL mice
CD3+T cells H1R activation Reduced IFN-γ
Decreased endothelial
adhesiveness
Lapilla et al., 2011
H2 MOG35–55
H2R-KO mice
APC Th1 Reduced cytokines
Inhibition of cell polarization
Less severe disease
Teuscher et al., 2004
MOG35–55
C57/Bl6
Proinflammatory
cells
H2R activation Less severe disease Emerson et al., 2002
PLP139–151
SJL mice
CD3+T cells H2R activation Reduced IFN-γ
Decreases endothelial
adhesivness
Lapilla et al., 2011
H3 MOG35–55
H3R-KO mice
Th1
Endothelial cells
Increased expression of
chemokines/chemokine
receptors
BBB deregulation
More severe disease
Teuscher et al., 2007
H4 MOG35–55
H4R-KO mice
Treg
Th17
Lower frequency
Higher frequency
More severe disease
del Rio et al., 2012
MOG35–55
C57/Bl6 mice
Th1
Mdc
H4R antagonism Increased IFN-γ,
reduced IL-10
More severe disease
Passani et al., 2011a
MOG35–55
HDC KO mice
CD3+T cells Increased IFN-γ, TNF,
More severe disease
Musio et al., 2006
APC, antigen presenting cells; BBB, blood brain barrier; mDC, myeloid dendritic cells; MOG35–55, Myelin Oligodendrocyte Glycoprotein; PLP139–151, Myelin
Proteolipid Protein.
production and their ability to drive CD4+ T-cell differentiation
to the Th2 phenotype. On the other hand, H4R activation modu-
lates chemotaxis (reviewed in Schneider et al., 2010). Depending
on the receptor engaged on polarized T cells, histamine can pro-
mote Th1 responses through H1R and down-regulate both Th1
and Th2 responses through H2R (Jutel et al., 2001). Similarly
to DCs, H1R and H4R activation on CD4+ T cells induces
chemotaxis in vitro, whereas H1R and H2R modulate cytokine
production (Schneider et al., 2010).
Mast cells are generally thought to be the major sources of his-
tamine and can themselves be modulated by histamine as they
express H1R, H2R, and H4R. There is ample correlative and direct
evidence that supports mast cell involvement in amplifying the
severity of both MS and EAE. Mast cell-deficient W/W(v) mice
exhibit significantly less severe disease than wild type littermates
in both progressive (Sayed et al., 2011) and relapsing-remitting
(Secor et al., 2000) models of EAE.
Susceptibility to EAE requires expression of Hrh1, the gene
encoding the H1R (Ma et al., 2002). The H1R is expressed on
Th1 cells in EAE mice brain lesions (Pedotti et al., 2003), where
its presence is necessary for full encephalitogenic expression
(Noubade et al., 2007). Furthermore, expression of the H1R is
up-regulated on encephalitogenic PLP139–151 specific Th1 com-
pared to Th2 cell lines (Pedotti et al., 2003). Not surprisingly,
specific pharmacological targeting of H1R results in amelioration
of EAE (Pedotti et al., 2003; El Behi et al., 2007) andH1R-deficient
(H1R-KO) mice exhibit a significant delay in the onset of EAE
and a reduction in the severity of the clinical signs compared with
WT mice (Ma et al., 2002; Table 1). In fact, CD4+ T-cells from
H1R-KO mice produce significantly less IFN-γ and more IL-4
(that induces differentiation of naive CD4+ T cells to Th2 cells)
in in vitro assays compared to wild-type controls, indicating that
H1R signaling in CD4+ T cells plays a central role in regulating
pathogenic T-cell responses (Ma et al., 2002).
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TheH2R also seems to partially regulate encephalitogenic Th1-
cell responses and EAE susceptibility, as H2R-KO mice develop
a less severe disease than wild-type littermates during the acute,
early phase (Teuscher et al., 2004). The failure of H2R-KOmice to
generate encephalitogenic Th1 effector cell responses is attributed
to H2R-mediated regulation of cytokine production by DCs that
affects T-cell-polarizing activity. In conclusion, H1R and H2R
seem to have a pro-inflammatory role and disease-promoting
effect, but the story is not quite as simple as that, as H1R or
H2R activation may also play an important role in limiting
autoimmune responses.
Adhesion of T cells to the inflamed microcirculation precedes
their penetration in the brain parenchyma, following breakdown
of BBB integrity. H1Rs are expressed on endothelial cells where
they increase vascular permeability (Owen et al., 1980); however,
functional expression of the H1R on endothelial cells does not
restore EAE susceptibility in H1R-KO mice, rather, overexpres-
sion of the H1R further suppresses the residual symptoms shown
by H1R-KO mice, suggesting that endothelial H1R signaling is
needed to maintain cerebrovascular integrity (Lu et al., 2010).
Pedotti and colleagues (Lapilla et al., 2011) have demonstrated
that histamine activating H1R and H2R, inhibits in vitro the pro-
liferation of mouse CD3+ T cells reactive against PLP139–151, and
their adhesiveness to the inflamed endothelium. Also, treatment
with an H2R agonist reduces the clinical signs of murine EAE
(Emerson et al., 2002; Table 1). As pointed out by the authors
(Pedotti et al., 2003; Lapilla et al., 2011) methodological differ-
ences may account for the discrepancies observed in in vivo and
ex vivo experiments, such as the immunization protocols adopted.
Also, ex vivo experiments may not necessarily recapitulate the
integrated action of signals relevant to EAE and components of
an integrated system maybe lost. On the other hand, genetically
modified micemay carry alterations of systems other than the tar-
geted ones, and activation of vicarious mechanisms may hinder
the effects related to the deleted gene(s). In fact, the complete lack
of HDC and histamine synthesis in HDC-KO mice exacerbates
EAE and increases the production of proinflammatory cytokines
(Musio et al., 2006). This phenotype does not seem to summarize
the lack of signaling at histamine receptors observed in H1R- and
H2R-deficient mice, rather a reduced effect of histamine at H3R
and H4R (see below).
As mentioned earlier, H3R are normally not expressed by
hematopoietic cells, but are mostly confined to the CNS where
they limit histamine synthesis and release (Arrang et al., 1983),
as well as regulate other neurotransmitters’ release (reviewed in
Passani and Blandina, 2011). It was recently shown that deletion
of the H3R leads to more severe EAE, an effect associated with
altered BBB permeability and an unexpected increased expression
of chemokines/chemokine receptors that promote entry into the
CNS on peripheral T cells that do not themselves express H3R
(Teuscher et al., 2007). The authors suggest that neuronal H3R
may serve as a central control of cerebrovascular tone, and nega-
tively regulate susceptibility to neuroinflammatory diseases. Their
proposed mechanism states that in H3R-KO mice the absence of
a presynaptic inhibition would lead to increased release of neuro-
transmitters andpostsynaptic activity thatwould exert neurogenic
control of BBB permeability and T cell chemokine profile.
THE COMPLEX ROLE OF H4R DURING INFLAMMATORY
RESPONSES IN EAE
The distribution of the H4R on immune cells and its primary role
in inflammatory functions has made it a very attractive target
for the treatment of asthma and autoimmune diseases (Bhatt
et al., 2010). Recent evidence has also shown the topological
and functional localization of the H4R in the CNS of both
humans and rodents (Connelly et al., 2009; Strakhova et al.,
2009). Immunohistochemical detection revealed that H4Rs are
expressed on the soma of sensory neurons with intense staining of
small and medium diameter neurons, as well as lamina I-II of the
lumbar spinal cord, where the immunoreactivity pattern suggests
localization with terminals of primary afferent neurons (Connelly
et al., 2009). These findings widen the range of therapeutic poten-
tials of compounds targeting the H4R, as antagonistsmight relieve
itching by decreasing not only inflammation, but also the urge to
scratch. The H4R is detected on hematopoietic progenitor cells
(Petit-Bertron et al., 2009), and its activation before exposure
to growth factors leads to a drastic decrease in the percentage
of cycling cells (Schneider et al., 2011). The H4R expression is
dynamic as it is up-regulated during the differentiation from
human monocytes to DCs (Gutzmer et al., 2005). In addition,
receptor levels may change with the progression of pathophysio-
logical responses, e.g., inflammatory stimuli can up-regulate the
expression of H4R in monocytes (Dijkstra et al., 2007). The anti-
inflammatory effect of H4R antagonists in asthma and pruritus
is consolidated (reviewed in Thurmond et al., 2008; Zampeli and
Tiligada, 2009). The use of selective antagonists demonstrated a
pro-inflammatory role for this receptor in several paradigms and
suggested a facilitating action on autoimmune diseases (Jadidi-
Niaragh and Mirshafiey, 2010). Furthermore H4R are expressed
on Th17 cells where their activation increases IL-17 production
(Mommert et al., 2012). Quite surprisingly though, mice with
a disrupted H4R gene develop more severe EAE together with
increased neuroinflammatory signs and increased BBB perme-
ability compared to wild type mice (del Rio et al., 2012). In this
paradigm, H4R-KO mice have a lower frequency of infiltrating
Treg cells that possess disease suppressive activity, more precisely
during CNS invasion at day 10 post immunization (10 dpi), and
a higher proportion of inflammatory Th17. Preliminary data in
our laboratory are corroborating these findings (Table 1), as H4R
antagonists such as JNJ7777120 administered daily for eight days
to EAE mice at the onset of clinical signs exacerbate the clinical
and neuropathological signs of the disease (Passani et al., 2011a).
In our model, a decreased release of regulatory cytokines such
as IL-10 is accompanied with augmented production of IFN-γ
in MOG35–55-specific T cells during the acute phase of the dis-
ease (18–20 dpi), suggesting a more complex role of H4R not only
on regulatory mechanisms of the immune response but also on
T effector cells.
In conclusion, the use of different inflammatory and immune
models is producing conflicting results about the role of the H4R
in allergic and immune responses. For example, recent data show
that the activation, and not antagonism, of H4R leads to reduced
pro-inflammatory capacity of a subpopulation of DCs found in
inflamed tissues in atopic dermatitis (Gschwandtner et al., 2011).
Also, in a murine model of allergic asthma, the administration
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of H4R agonists mitigated airway hyperreactivity and inflamma-
tion with a suggested direct effect on T regulatory cell recruitment
(Morgan et al., 2007). It is clear that in the context of the
conflicting activities of the H4R that depend on its activation
on different hematopoietic cells, additional research is needed to
clarify whether H4R agonists can yield promising drugs in the
treatment of autoimmune diseases.
CONCLUSIONS
Histamine receptors play multiple roles in immune reactions and
autoimmune disorders. Strategies aimed at interfering with the
histamine axis may have relevance in the therapy of autoim-
mune diseases of the CNS as histamine may determine, through
different receptor activation pathways, a shift in T helper cell sub-
population,may influencemigration of lymphocytes andmyeloid
cells during CNS invasion, interfere with antigen presentation
at the immune synapse level and finally, determine variations in
normal neuronal functions. It will be of paramount importance
to define the temporal sequence of histamine receptor activa-
tion during disease initiation in peripheral tissues and during
CNS invasion. Hopefully, this will help the scientific community
to put the sometimes confusing and contradictory observations
reviewed here into better focus and provide a perspective for eval-
uating potential therapeutic interventions using histaminergic
compounds.
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